Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats
Pulmonary arterial hypertension is a severe respiratory disease characterized by pulmonary artery remodeling. RV dysfunction and dysregulated circulating metabolomics are associated with adverse outcomes in pulmonary arterial hypertension. We investigated effects of tadalafil and macitentan alone or...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-11-01
|
Series: | Pulmonary Circulation |
Online Access: | https://doi.org/10.1177/2045894020947283 |
id |
doaj-f12a5a6e63d44ffdb2021cbce29d7c48 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Argen Mamazhakypov Astrid Weiß Sven Zukunft Akylbek Sydykov Baktybek Kojonazarov Jochen Wilhelm Christina Vroom Aleksandar Petrovic Djuro Kosanovic Norbert Weissmann Werner Seeger Ingrid Fleming Marc Iglarz Friedrich Grimminger Hossein A. Ghofrani Soni S. Pullamsetti Ralph T. Schermuly |
spellingShingle |
Argen Mamazhakypov Astrid Weiß Sven Zukunft Akylbek Sydykov Baktybek Kojonazarov Jochen Wilhelm Christina Vroom Aleksandar Petrovic Djuro Kosanovic Norbert Weissmann Werner Seeger Ingrid Fleming Marc Iglarz Friedrich Grimminger Hossein A. Ghofrani Soni S. Pullamsetti Ralph T. Schermuly Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats Pulmonary Circulation |
author_facet |
Argen Mamazhakypov Astrid Weiß Sven Zukunft Akylbek Sydykov Baktybek Kojonazarov Jochen Wilhelm Christina Vroom Aleksandar Petrovic Djuro Kosanovic Norbert Weissmann Werner Seeger Ingrid Fleming Marc Iglarz Friedrich Grimminger Hossein A. Ghofrani Soni S. Pullamsetti Ralph T. Schermuly |
author_sort |
Argen Mamazhakypov |
title |
Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats |
title_short |
Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats |
title_full |
Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats |
title_fullStr |
Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats |
title_full_unstemmed |
Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats |
title_sort |
effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats |
publisher |
SAGE Publishing |
series |
Pulmonary Circulation |
issn |
2045-8940 |
publishDate |
2020-11-01 |
description |
Pulmonary arterial hypertension is a severe respiratory disease characterized by pulmonary artery remodeling. RV dysfunction and dysregulated circulating metabolomics are associated with adverse outcomes in pulmonary arterial hypertension. We investigated effects of tadalafil and macitentan alone or in combination on the RV and plasma metabolomics in SuHx and PAB models. For SuHx model, rats were injected with SU5416 and exposed to hypoxia for three weeks and then were returned to normoxia and treated with either tadalafil (10 mg/kg in chow) or macitentan (10 mg/kg in chow) or their combination (both 10 mg/kg in chow) for two weeks. For PAB model, rats were subjected to either sham or PAB surgery for three weeks and treated with above-mentioned drugs from week 1 to week 3. Following terminal echocardiographic and hemodynamic measurements, tissue samples were collected for metabolomic, histological and gene expression analysis. Both SuHx and PAB rats developed RV remodeling/dysfunction with severe and mild plasma metabolomic alterations, respectively. In SuHx rats, tadalafil and macitentan alone or in combination improved RV remodeling/function with the effects of macitentan and combination therapy being superior to tadalafil. All therapies similarly attenuated SuHx-induced changes in plasma metabolomics. In PAB rats, only macitentan improved RV remodeling/function, while only tadalafil attenuated PAB-induced changes in plasma metabolomics. |
url |
https://doi.org/10.1177/2045894020947283 |
work_keys_str_mv |
AT argenmamazhakypov effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats AT astridweiß effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats AT svenzukunft effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats AT akylbeksydykov effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats AT baktybekkojonazarov effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats AT jochenwilhelm effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats AT christinavroom effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats AT aleksandarpetrovic effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats AT djurokosanovic effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats AT norbertweissmann effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats AT wernerseeger effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats AT ingridfleming effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats AT marciglarz effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats AT friedrichgrimminger effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats AT hosseinaghofrani effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats AT sonispullamsetti effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats AT ralphtschermuly effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats |
_version_ |
1724424544631914496 |
spelling |
doaj-f12a5a6e63d44ffdb2021cbce29d7c482020-11-25T04:08:40ZengSAGE PublishingPulmonary Circulation2045-89402020-11-011010.1177/2045894020947283Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive ratsArgen Mamazhakypov0Astrid Weiß1Sven Zukunft2Akylbek Sydykov3Baktybek Kojonazarov4Jochen Wilhelm5Christina Vroom6Aleksandar Petrovic7Djuro Kosanovic8Norbert Weissmann9Werner Seeger10Ingrid Fleming11Marc Iglarz12Friedrich Grimminger13Hossein A. Ghofrani14Soni S. Pullamsetti15Ralph T. Schermuly16Cardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanyCardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanyInstitute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany & German Center of Cardiovascular Research (DZHK), Partner site RheinMain, Frankfurt am Main, GermanyCardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanyCardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanyCardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanyCardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanyCardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanySechenov First Moscow State Medical University (Sechenov University), Moscow, RussiaCardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanyDepartment of Lung Development and Remodelling, Max-Planck Institute for Heart and Lung Research, Bad Nauheim, GermanyInstitute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany & German Center of Cardiovascular Research (DZHK), Partner site RheinMain, Frankfurt am Main, GermanyActelion Pharmaceuticals Ltd, Allschwil, SwitzerlandCardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanyCardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanyDepartment of Lung Development and Remodelling, Max-Planck Institute for Heart and Lung Research, Bad Nauheim, GermanyCardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanyPulmonary arterial hypertension is a severe respiratory disease characterized by pulmonary artery remodeling. RV dysfunction and dysregulated circulating metabolomics are associated with adverse outcomes in pulmonary arterial hypertension. We investigated effects of tadalafil and macitentan alone or in combination on the RV and plasma metabolomics in SuHx and PAB models. For SuHx model, rats were injected with SU5416 and exposed to hypoxia for three weeks and then were returned to normoxia and treated with either tadalafil (10 mg/kg in chow) or macitentan (10 mg/kg in chow) or their combination (both 10 mg/kg in chow) for two weeks. For PAB model, rats were subjected to either sham or PAB surgery for three weeks and treated with above-mentioned drugs from week 1 to week 3. Following terminal echocardiographic and hemodynamic measurements, tissue samples were collected for metabolomic, histological and gene expression analysis. Both SuHx and PAB rats developed RV remodeling/dysfunction with severe and mild plasma metabolomic alterations, respectively. In SuHx rats, tadalafil and macitentan alone or in combination improved RV remodeling/function with the effects of macitentan and combination therapy being superior to tadalafil. All therapies similarly attenuated SuHx-induced changes in plasma metabolomics. In PAB rats, only macitentan improved RV remodeling/function, while only tadalafil attenuated PAB-induced changes in plasma metabolomics.https://doi.org/10.1177/2045894020947283 |